Pfizer Inc. (NYSE: PFE) and Moderna Inc. (NASDAQ: MRNA) have made significant progress in their efforts to develop a vaccine against the
Pfizer Inc.
-(PFE)
XNYS:PFE
Earnings calendar for the week of Nov. 16
Taking cues from the election verdict and positive data from Pfizer's COVID vaccine trial, major Wall Street indexes made strong gains early
Pfizer (PFE) gains on data showing 90% efficacy for COVID-19 vaccine candidate
Shares of Pfizer Inc. (NYSE: PFE) rallied on Monday after the company reported positive results from its Phase 3 trial for its
Pfizer Inc (PFE) Q3 2020 Earnings Call Transcript
Pfizer Inc. (NYSE: PFE) Q3 2020 Earnings Call dated Oct. 27, 2020. Corporate Participants: Chuck Triano -- Senior Vice President, Investor Relations Albert Bourla -- Chairman
Pfizer (PFE) posts mixed results in Q3
Pfizer Inc (NYSE: PFE) reported third-quarter 2020 financial results before the opening bell on Tuesday. The pharmaceutical giant reported a 4% decline
COVID-19 vaccine development: A look at some of the pharma companies and their progress
The COVID-19 pandemic continues to go on and while the world is slowly coming out of the previously imposed strict lockdown, things
Pfizer Inc. (PFE) Q2 2020 Earnings Call Transcript
Pfizer Inc. (NYSE: PFE) Q2 2020 earnings call dated July 28, 2020 https://youtu.be/aJVrijDiyOk Corporate Participants: Chuck Triano -- Senior Vice President, Investor Relations Albert
Pfizer (PFE) raises outlook on hopes of prescription trends recovery and COVID-19 vaccine progress
Shares of Pfizer Inc. (NYSE: PFE) were up more than 4% on Tuesday after the company beat revenue and earnings estimates for
Key highlights from Pfizer (PFE) Q2 2020 earnings results
Pfizer Inc. (NYSE:PFE) reported second quarter 2020 earnings results today. Revenues fell 11% to $11.8 billion. The decline was 9% on an
Pfizer (NYSE: PFE) Q1 2020 Earnings Call Transcript
Pfizer Inc. (PFE) Q1 2020 earnings call dated April 28, 2020 Corporate Participants: Chuck Triano -- Senior Vice President, Investor Relations Albert Bourla -- Chairman and
A visual representation of Pfizer Inc. (NYSE: PFE) Q1 2020 earnings results
Pfizer Inc. (NYSE: PFE) Tuesday reported a decline in first-quarter earnings and revenues. However, the results exceeded analysts' forecast. Earnings, on an
Pfizer Inc (NYSE: PFE) Q4 2019 Earnings Call Transcript
Pfizer Inc (NYSE: PFE) Q4 2019 Earnings Conference Call January 28, 2020 Corporate participants: Chuck Triano -- Senior Vice President, Investor Relations Albert Bourla -- Chairman
Pfizer (PFE) reports better-than-expected Q3 results; stock gains
Drugmaker Pfizer (NYSE: PFE) reported lower revenues and earnings for the third quarter. The results, however, topped the market's expectations. The management
Pfizer’s stock suffers as Q2 results and Mylan deal fail to impress Wall Street
Pfizer Inc.’s (NYSE: PFE) shares continue to trade in red after the company narrowly missed revenue estimates for the second quarter of
Earnings preview: A look at key factors affecting Pfizer’s Q2 results
Pfizer Inc. (NYSE: PFE) is scheduled to report second quarter 2019 earnings results on Tuesday, July 30, before market open. Analysts expect
Pfizer secures FDA approval for oncology biosimilar Zirabev; stock gains
A day after appointing former FDA chief Scott Gottlieb to its board of directors, pharma giant Pfizer (PFE) said it received FDA
What the future holds for generic drug industry
The size of the generic drug market in the US is so large that about 90% of all prescription medicines sold last
Pharma stocks: Merck is on a buying spree
Several merger and acquisition deals are being announced in the healthcare sector, the most recent one being the acquisition of Array Biopharma
Pfizer boosts oncology portfolio with $10-Bil acquisition of Array Biopharma
In a sign that the consolidation wave that swept in the pharmaceutical industry last year is likely to continue, Pfizer (NYSE: PFE)
What’s in store for top pharma stocks this year
The stocks of leading pharmaceutical firms shifted to growth mode this year after winding up 2018 on a low note, in line
Intercept Pharmaceuticals reports mixed Q1 results
Intercept Pharmaceuticals (NASDAQ: ICPT) reported wider-than-expected losses in the first quarter of 2019, primarily due to higher R&D expenses related to NASH